In 2010, genetically defined subgroups of medulloblastoma were introduced dividing medulloblastoma into four different entities (wnt-activated, SHH-activated with p53 wild-type/SH-activated with mutated p53 Group 3 and Group 4) with distinct characteristics and prognoses [81]. This evidence concerns the gene TP53 and medulloblastoma.